Evidence map›Paper›PMID 36349496›Full record

ArticlePsychiatric services (Washington, D.C.)2023

Smoking Cessation Medication Prescribing for Smokers With and Without Mental Illness.

Sarah A White, Elizabeth Stone, Karly A Murphy, Gail L Daumit, Emma E McGinty

Open access · greenAbstract read
In one paragraph

Article in Psychiatric services (Washington, D.C.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sarah A WhiteDepartment of Health Policy and Management (White, Stone, McGinty), Johns Hopkins Bloomberg School of Public Health, and Division of General Internal Medicine, Johns Hopkins School of Medicine (Murphy, Daumit), Baltimore.
Elizabeth StoneDepartment of Health Policy and Management (White, Stone, McGinty), Johns Hopkins Bloomberg School of Public Health, and Division of General Internal Medicine, Johns Hopkins School of Medicine (Murphy, Daumit), Baltimore.
Karly A MurphyDepartment of Health Policy and Management (White, Stone, McGinty), Johns Hopkins Bloomberg School of Public Health, and Division of General Internal Medicine, Johns Hopkins School of Medicine (Murphy, Daumit), Baltimore.
Gail L DaumitDepartment of Health Policy and Management (White, Stone, McGinty), Johns Hopkins Bloomberg School of Public Health, and Division of General Internal Medicine, Johns Hopkins School of Medicine (Murphy, Daumit), Baltimore.
Emma E McGintyDepartment of Health Policy and Management (White, Stone, McGinty), Johns Hopkins Bloomberg School of Public Health, and Division of General Internal Medicine, Johns Hopkins School of Medicine (Murphy, Daumit), Baltimore.
Johns Hopkins University · US

Funding

Using an innovative quality improvement process to increase delivery of evidenced-based CVD risk factor care in community mental health organizationsP50MH115842 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Gail L. Daumit · 2018 to 2026
$16.2M
Mental Health Services and Systems Training ProgramT32MH109436 · NIMH · JOHNS HOPKINS UNIVERSITY · PI Matthew Eisenberg, Elizabeth A. Stuart · 2017 to 2026
$1.7M
NIMH NIH HHS P50 MH115842NIMH NIH HHS T32 MH109436
6 · The paper itself

Abstract

objectiveThis study examined trends in receipt of smoking cessation medications among smokers with and without mental illness, including serious mental illness, from 2005 to 2019 and characterized physician attitudes and practices related to tobacco screening and cessation treatment.

methodsMedical Expenditure Panel Survey (MEPS) data (2005-2019) were examined for receipt of cessation medication prescriptions for bupropion, varenicline, and nicotine replacement therapy (NRT) among 55,662 smokers-18,353 with any mental illness and 7,421 with serious mental illness. Qualitative interviews with 40 general internists and psychiatrists between October and November 2017 used a semistructured guide. MEPS data were analyzed with descriptive statistics, and interviews were analyzed with hybrid inductive-deductive coding.

resultsFrom 2005 to 2019, at least 83% of smokers with or without mental illness did not receive varenicline, NRT, or bupropion. Over 14 years, the proportion of smokers receiving varenicline peaked at 2.1% among those with no mental illness, 2.9% among those with any mental illness, and 2.4% among those with serious mental illness. The respective peak proportions for NRT were 0.4%, 1.1%, and 1.6%; for bupropion, they were 1.2%, 8.4%, and 16.7%. Qualitative themes were consistent across general internists and psychiatrists; providers viewed cessation treatment as challenging because of the perception of smoking as a coping mechanism and agreed on barriers to treatment, including lack of insurance coverage and contraindications for people with mental illness.

conclusionsSystem- and provider-level strategies to support evidence-based smoking cessation treatment for people with and without mental illness are needed.

Indexed as

Smoking CessationBupropionHumansNicotinic AgonistsSmokersTobacco Use Cessation DevicesVareniclineBupropionNicotinic AgonistsVareniclineDrug treatment/psychopharmacologySmoking

Identifiers

PMID36349496
PMCPMC10066821
OpenAlexW4308638744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.